GSE19862Prediction of response to bevacizumab
Homo sapiens
12 Downloadable Samples
Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)Submitter Supplied Information
Description
The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received bevacizumab therapy as first line or second line treatment. Responders and nonresponders were determined based on RECIST and confirmed by CT or MRI. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133.
PubMed ID
No associated PubMed ID
Publication Title
No associated publication
Total Samples
14
Submitter’s Institution
Authors
No associated authors
Source Repository
Alternate Accession IDs
Samples
Show of 0 Total Samples
Filter
Add/Remove
Accession Code
Title
Specimen part
Processing Information
Additional Metadata
Loading...
Some fields may be harmonized. Learn more